Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

he method of accounting for our convertible notes. In addition, as required, we revised our previously reported financial statements to retrospectively apply this change in accounting to prior periods. We believe that excluding the non-cash portion of our interest expense allows management and investors an alternative view of our financial results "as if" our net income reflected only the cash portion of our interest expense.

2. Purchase accounting and product acquisition related adjustments: Non-GAAP adjusted net income excludes certain items related to the acquisition of Cinryze and Vancocin. The excluded items include charges related to amortization and step up in the value of Cinryze inventory. Excluding these charges allows management and investors an alternative view of our financial results "as if" the acquired intangible asset had been developed internally rather than acquired and, therefore, provides a supplemental measure of performance in which the Company's acquired intellectual property is treated in a comparable manner to its internally developed intellectual property.

3. Stock option expense - Non-GAAP adjusted net income excludes the impact of our stock option expense recorded in accordance with SFAS No. 123R. We believe that excluding the impact of expensing stock options better reflects the recurring economic characteristics of our business.

4. Other items - Non-GAAP net income and diluted EPS exclude other unusual or non-recurring items that are evaluated on an individual basis. Our evaluation of whether to exclude an item for purposes of determining our non-GAAP financial measures considers both the quantitative and qualitative aspects of the item, including, among other things (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. For purposes of det
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... August 01, 2015 , ... The Honor Society ... Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, ... participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, the Mesothelioma ... store can be accessed by visiting http://www.curemeso.org/store . , “Our new store ... best part: whenever a product is purchased, the Meso Foundation receives a $5.00 ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, ... has re-branded their social media profiles to better connect with the public. The ... communicate, find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge ...
(Date:7/31/2015)... Los Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... of surgeons and cosmetic experts gathered to see if they could reach a consensus ... procedures, including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on ...
(Date:7/31/2015)... ... 2015 , ... The 2015 New York Regional Conference on ... professionals, and researchers, covering a variety of topics related to mesothelioma and presented ... the Mesothelioma Applied Research Foundation and Memorial Sloan Kettering Cancer Center. , The ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3
... India's Knowledge Commission will soon come up with recommendations ... level to make it more competitive//, and to accommodate ... ,"We will come up with recommendations on the undergraduate ... he said, adding that a group has also been ...
... Research Institute at the University of Massachusetts listed about ... pollution//. This list is officially called the Toxic 100. ... of air pollution. This is based on air releases ... United States. , The various factors that ...
... to cancer is expected to be unsuccessful. Statisticians with the ... invested in the hunt for common inherited genetic variants that ... that there are a number of problems when doing such ... is that common genes are unlikely to exist nor ...
... enter the Guinness Book of World Records, but her achievement ... of 11 definitely makes her a wonder-kid. ,Born ... a medical practitioner, passed her Class 12 exam in the ... in the Basbadanpura area of this Rajasthan capital. ...
... coffee, coffee drinkers finally have something to cheer about. A ... three cups of coffee are protected from heart disease to ... Women's Health Study and has found that up to 60 ... free radicals in our bodies may come from coffee. ...
... be presented at the 29th Annual Scientific Sessions of ... that following// a methodical desensitization protocol might help patients ... to prevent the formation of new blockages in coronary ... to patients and physicians, and can lead to discontinuation ...
Cached Medicine News:Health News:Jaipur Girl’s Rare Feat: The Youngest To Pass Class 12 At The Age Of 1 2Health News:Clopidogrel Allergy Can Be Tackled By Methodical Desensitization 2
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
(Date:7/30/2015)... 30, 2015  EP Global Communications, Inc. (Public OTC: ... contacted the Company about discussing EPGL,s electronic contact ... Monday, August 3, 2015.  Novartis CEO Joe ... the coming electronic contact lens market could be ... next several years.  Novartis partnered with Google in ...
(Date:7/30/2015)... Calif., July 30, 2015  Amgen (NASDAQ: ... second quarter of 2015. Key results include: ... second quarter of 2014 to $5,370 million, with ... Enbrel ® (etanercept), Prolia ® (denosumab), ... and XGEVA ® (denosumab). Unfavorable changes in ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... Dong-A PharmTech Co. Ltd., announced that its ... III trials for udenafil, a new long acting drug ... double-blind, placebo-controlled trial is designed to evaluate the safety ... of phosphodiesterase versus placebo. The trials will be ...
... Nov. 4 CVS Caremark (NYSE: CVS ) ... position of SVP, Marketing for its pharmacy benefit management ... marketing from Jack Bruner, who is transitioning to the ... http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , Greer brings ...
Cached Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development 2Company Appoints New SVP, Marketing for PBM Business 2
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... of acute low back pain, they want ... restores functional mobility by providing powerful compression ... sizes that correspond directly to men's or ... reduce inventory requirements while simplifying the fitting ...
... effective immobilization of the cervical and upper ... that makes it well tolerated by patients. ... going from a stand-alone cervical collar, to ... a four-post orthosis. For these reasons, the ...
... laborious custom fabrication was required to produce ... and modifications in response to patient complaints ... evolved from two years of development and ... This orthosis can be quickly adjusted to ...
Medicine Products: